Business Context and Reporting Period
MacroGenics, Inc. filed this Form 8-K on October 16, 2013, to report the completion of its initial public offering (IPO) and concurrent amendments to its corporate governance documents. The company is incorporated in Delaware and is based in Rockville, Maryland.
Key Financial Metrics
The filing details the IPO transaction but does not provide historical revenue, profit, cash flow, or margin data.
- Shares Sold: 5,750,000 shares of common stock (including 750,000 shares from the full exercise of the underwriters' option).
- Offering Price: $16.00 per share.
- Shares Outstanding: 25,020,288 shares of common stock as of October 17, 2013.
- Reserved Shares: 3,151,226 shares reserved for issuance upon exercise of outstanding employee stock options.
- Preferred Stock: No shares outstanding; 5,000,000 shares of undesignated preferred stock authorized.
Material Changes
The primary material change is the transition from a private to a public company via the IPO. Additionally, the company amended its Certificate of Incorporation and Bylaws to:
- Reduce authorized common stock from 425,000,000 to 125,000,000 shares.
- Correct the par value of authorized stock to $0.01 per share via a Certificate of Correction.
- Establish a classified board of directors with staggered three-year terms.
- Eliminate the ability of stockholders to take action by written consent or call special meetings.
- Require a 75% affirmative vote to remove directors for cause.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the structural changes to corporate governance. The filing notes that the IPO closing was announced via a press release incorporated by reference.
Investor Verification Checklist
- Verify the total gross proceeds from the IPO by multiplying the 5,750,000 shares sold by the $16.00 offering price.
- Review the attached Restated Certificate of Incorporation (Exhibit 3.1) and Amended and Restated By-Laws (Exhibit 3.2) for full details on governance restrictions.
- Confirm the exact number of shares outstanding post-IPO, noting the 25,020,288 figure reported as of October 17, 2013.
- Check the press release (Exhibit 99.1) for details on the use of proceeds and underwriting discounts.